July 26th 2024
The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
GVHD Prophylaxis After TBI Decreases Rates of GVHD in Hematologic Malignancies
April 25th 2022Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies
Read More
Envisioning a Path Forward for PI3K inhibitors in Hematologic Malignancies
April 25th 2022In an interview with Targeted Oncology, Basem Goueli, MD, PhD, MBA, discussed the recent crackdown on PI3K inhibitors and how this drug class may fit into future treatment for hematologic malignancies as well as solid tumors.
Read More
FDA’s ODAC Votes Yes to Requiring Randomized Data for Future PI3Ki Approvals in Hematologic Cancers
April 21st 2022In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee has voted yes to future approvals of PI3K inhibitors being supported by randomized data given observed toxicities in the drug class, research showing a detriment in OS, a narrow range between effective, and toxic doses.
Read More
Non-Response to Blinatumomab Shows Significant Association With Worse Survival Outcomes in B-ALL
April 6th 2022In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.
Read More
Addition of Lenalidomide to SOC Shows Feasibility, Safety in MDS, AML and CMML
April 3rd 2022AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.
Read More
Phase 1b/2 Study To Evaluate AUTO1 CAR T Cells in Relapsed/Refractory Adult B-Cell ALL
March 29th 2022Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Read More
FDA Postpones Decision on Luspatercept-aamt for Anemia in Adults With NTD Beta Thalassemia
March 25th 2022The FDA is no longer conducting a speedy review of the supplemental biologics license application for luspatercept-aamt as treatment for anemia in adults with non-transfusion-dependent beta thalassemia.
Read More
3 Trials Support Use of Naïve T-Cell Depletion Strategy in PBSC Grafts to Prevent Chronic GVHD
March 25th 2022Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.
Read More